Irish-listed Amryt Pharma posted operating losses before tax of €7.8m following a number of strategic acquisitions over the course of 2016. The company said that it had signed an exclusive licensing agreement with Aegerion Pharmaceuticals in December, which it said could have a transformational effect on the business. Amryt specialises in creating drugs to treat […]